<DOC>
	<DOCNO>NCT01646307</DOCNO>
	<brief_summary>This randomize , open label , parallel-group study design investigate whether periprocedural intensive statin therapy atorvastatin versus rosuvastatin administration PCI 30-day continuous intensive treatment superior usual care , term cardiovascular event Chinese elderly patient .</brief_summary>
	<brief_title>Effect Atorvastatin Versus Rosuvastatin Intensive Statin Regimens Chinese Elderly Patients Undergoing PCI</brief_title>
	<detailed_description>1800 elderly patient ( &gt; 65 yr ) coronary artery disease undergo elective PCI randomize 2:1 fashion either intensive statin group standard care group . Patients intensive statin group randomize two subgroup : administrate either atorvastatin 80mg 12h prior PCI , 40mg 2h prior PCI , follow 40 mg/d 30 day PCI ; rosuvastatin 20mg 12h prior PCI , 10mg 2h prior PCI ; follow 10 mg/d 30 day PCI , standard care group receive atorvastatin 20 mg/d . After angiography , patient undergo PCI procedure exclude study selection failure . The last visit 6 month PCI . Clinical data troponin , CK-MB , Scr , CCR , ALT , AST 24h 48h procedure record . 1000 eligible patient finally enrolled.The study conduct 12 center China .</detailed_description>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>6580 year old Patients undergoing elective percutaneous coronary intervention Evidence personally sign date informed consent document Patients undergoing emergency percutaneous coronary intervention Taking , need take atorvastatin 20mg/d equivalent statin ( simvastatin 20mg/d , pruvastatin 40mg/d , fluvastatin 80mg/d rovastatin 5mg/d ) next 6 month , need take fibrates niacin simultaneously accord investigator ' judgment . LDLC &lt; 1.8mmol/L patient without statin therapy Endstage congestive heart failure , LVEF &lt; 30 % Active hepatic disease hepatic dysfunction , AST/ALT &gt; 1.5UNL Myopathy increase creatine kinase ( CK &gt; 2 UNL ) WBC &lt; 4×109/L PLT &lt; 100×109/L Severe renal dysfunction ( Scr &gt; 3 mg/dl 264μmol/L ) Allergic experience serious adverse reaction HMGCoA reductase , ineligible take statin investigator 's judgment Severe aortic valve stenosis severe mitral stenosis , Obstructive hypertrophic cardiomyopathy , pericardial disease Accompanied malignant disease disease , cause life expectancy &lt; 6 month Participating interventional clinical trial use drug device Patients condition , investigator 's judgment , might increase risk subject adverse event abnormal laboratory find</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>